vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1394Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESОСОБЕННОСТИ ЛИПИДНОГО СПЕКТРА ДЕТЕЙ, СТРАДАЮЩИХ ЮНОШЕСКИМ АРТРИТОМLIPID PROFILE IN CHILDREN WITH RHEUMATOID ARTHRITISГудковаЕ.Ю.GudkovaE.Yu.АлексееваЕ.И.AlexeevaE.I.ГордеевГ.Ф.GordeevG.F.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowRussian Federation20080511201573Вопросы современной педиатрии2632Copyright © Гудкова Е., Алексеева Е., Гордеев Г., 20082008Гудкова Е., Алексеева Е., Гордеев Г.Gudkova E., Alexeeva E., Gordeev G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1394ReferencesЧазов Е.И., Климов А.Н. Дислипопротеинемии и ишемическая болезнь сердца. М.:Медицина. 1980. 312 с.Чазов Е.И., Климов А.Н. Дислипопротеинемии и ишемическая болезнь сердца. М.:Медицина. 1980. 312 с.Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influens of disease, activity, and anticardiolipin antibodies. Lupus. 1997; 6 (6): 533–539.Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influens of disease, activity, and anticardiolipin antibodies. Lupus. 1997; 6 (6): 533–539.Borba E.F., Santos R.D., Bonfa E. et al. Lipoprotein (a) levels in systemic lupus erythematosus. J. Rheumatol. 1994; 21: 220–223.Borba E.F., Santos R.D., Bonfa E. et al. Lipoprotein (a) levels in systemic lupus erythematosus. J. Rheumatol. 1994; 21: 220–223.Situnayake R. D., Kitas G. Dislipidemia and rheumatoid arthritis. Ann. Rheum. Dis. 1997; 56: 341–343.Situnayake R. D., Kitas G. Dislipidemia and rheumatoid arthritis. Ann. Rheum. Dis. 1997; 56: 341–343.Petri M. Thrombosis and systemic lupus erythematosis: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol. 1996; 25: 191–193.Petri M. Thrombosis and systemic lupus erythematosis: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol. 1996; 25: 191–193.Dessein P.H., Joffe B.I., Stamwix A.E. et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J. Rheumatol. 2003; 30: 1403–1405.Dessein P.H., Joffe B.I., Stamwix A.E. et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J. Rheumatol. 2003; 30: 1403–1405.Tam L.S., Tomlinson B., Chu T.T. et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (9): 1495–1498.Tam L.S., Tomlinson B., Chu T.T. et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (9): 1495–1498.Kiortsis D.N., Mavridis A.K., Filippatos T.D. et al Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 2006; 33 (5): 921–923.Kiortsis D.N., Mavridis A.K., Filippatos T.D. et al Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 2006; 33 (5): 921–923.Rosenson R. S. Myocardial injury: the acute phase response and lipoprotein metabolism. J. Amer. Coll. Cardiol. 1993; 22: 933–940.Rosenson R. S. Myocardial injury: the acute phase response and lipoprotein metabolism. J. Amer. Coll. Cardiol. 1993; 22: 933–940.Lourida E.S., Georgiadis A.N., Papavasiliou E.C. et al. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res. Ther. 2007; 9 (1): 19.Lourida E.S., Georgiadis A.N., Papavasiliou E.C. et al. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res. Ther. 2007; 9 (1): 19.Dessein P.H., Joffe B.I., Stamwix A.E. et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J. Rheumatol . 2003; 30: 1403–1405.Dessein P.H., Joffe B.I., Stamwix A.E. et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J. Rheumatol . 2003; 30: 1403–1405.Seriolo B., Paolino S., Sulli A. et al. Effects of anti–TNF alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N Y Acad. Sci. 2006; 1069: 414–419.Seriolo B., Paolino S., Sulli A. et al. Effects of anti–TNF alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N Y Acad. Sci. 2006; 1069: 414–419.Tam L.S., Tomlinson B., Chu T.T. et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (9): 1495–1498.Tam L.S., Tomlinson B., Chu T.T. et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (9): 1495–1498.Kiortsis D.N., Mavridis A.K., Filippatos T.D. et al Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006; 33 (5): 921–923.Kiortsis D.N., Mavridis A.K., Filippatos T.D. et al Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006; 33 (5): 921–923.van Halm V.P., Nielen M.M., Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66 (2): 184–188.van Halm V.P., Nielen M.M., Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66 (2): 184–188.Shah P.K., Yano J., Reyes O. et al. High-dose recombinant apolipoprotein A–1 (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein C–deficient mice: potencial implications for acute plaque stabilization. Circulation. 2001; 103: 3047–3050.Shah P.K., Yano J., Reyes O. et al. High-dose recombinant apolipoprotein A–1 (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein C–deficient mice: potencial implications for acute plaque stabilization. Circulation. 2001; 103: 3047–3050.Remanley A.T., Thomas F., Stonik J.A. et al. Synthetic amphipathic hetical peptides promote lipid efflux from cells by an ABCA1 dependent and an ABCA1 independent path way. J. Lipid. Res. 2003; 44: 828–836.Remanley A.T., Thomas F., Stonik J.A. et al. Synthetic amphipathic hetical peptides promote lipid efflux from cells by an ABCA1 dependent and an ABCA1 independent path way. J. Lipid. Res. 2003; 44: 828–836.Martinez L.O., Agerholm–Larsen B., Wang N. et al. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and reversed by ApoA–1. J. Biol. Chem. 2003; 373: 68–74.Martinez L.O., Agerholm–Larsen B., Wang N. et al. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and reversed by ApoA–1. J. Biol. Chem. 2003; 373: 68–74.Zhang Y., Zanotti I., Reilly M.P. et al. Overexpression of apolipoprotein A–1 promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003; 108: 661–663.Zhang Y., Zanotti I., Reilly M.P. et al. Overexpression of apolipoprotein A–1 promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003; 108: 661–663.Cockerill G.W., Rye K.A., Gamble J.R. et al. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1987–1994.Cockerill G.W., Rye K.A., Gamble J.R. et al. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1987–1994.Calabresi L., Franceschini G., Sirtori C.R. et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high dencity lipoproteins. Biochem. Biophys. Res. Commun. 1997; 238: 61–65.Calabresi L., Franceschini G., Sirtori C.R. et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high dencity lipoproteins. Biochem. Biophys. Res. Commun. 1997; 238: 61–65.Barter P.J., Baker P.W., Rye K.A. Effect of high density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol. 2002; 13: 285–288.Barter P.J., Baker P.W., Rye K.A. Effect of high density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol. 2002; 13: 285–288.McMahon M., Grossman J., FitzGerald J. et al. Proinflammatory high density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006; 54 (8): 2541–2549.McMahon M., Grossman J., FitzGerald J. et al. Proinflammatory high density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006; 54 (8): 2541–2549.Насонов Е.Л Ревматоидный артрит — модель атеротромбоза. РМЖ. 2005; 13 (8): 509-512.Насонов Е.Л Ревматоидный артрит — модель атеротромбоза. РМЖ. 2005; 13 (8): 509-512.Cassidy P.L. Textbook of Pediatric Rheumatology. 5th edition. USA. 2006.Cassidy P.L. Textbook of Pediatric Rheumatology. 5th edition. USA. 2006.
The authors declare that there are no conflicts of interest present.